Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 6/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.40 |
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.40 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.39 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.39 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.39 |
| ▸ | HTR1A | P08908 | 2/20 | 0.33 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.31 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22488274 | 1.00 | SLC6A2 (0.40) | SLC6A2SLC6A4SLC6A3KCNH2CHRM2 | |
| SCHEMBL22488273 | 1.00 | SLC6A2 (0.40) | SLC6A2SLC6A4SLC6A3KCNH2CHRM2 | |
| Hydrochloric Acid SCHEMBL17220468 | 0.98 | SLC6A2 (0.39) | SLC6A2SLC6A4SLC6A3KCNH2CHRM2 | |
| Hydrochloric Acid SCHEMBL15477133 | 0.98 | SLC6A2 (0.39) | SLC6A2SLC6A4SLC6A3KCNH2CHRM2 | |
| Hydrochloric Acid SCHEMBL795912 | 0.98 | SLC6A2 (0.39) | SLC6A2SLC6A4SLC6A3KCNH2CHRM2 | |
| SCHEMBL15421741 | 0.88 | CHRNB2 (0.41) | SLC6A2CHRM2CHRM1CHRM3HTR1A | |
| SCHEMBL408304 | 0.87 | HTR2C (0.35) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL12321050 | 0.82 | SLC6A4 (0.31) | SLC6A2SLC6A4SLC6A3 | |
| Hydrochloric Acid SCHEMBL17255450 | 0.80 | CYP2D6 (0.30) | SLC6A2SLC6A4SLC6A3 | |
| Acetic Acid SCHEMBL437553 | 0.76 | PMP22 (0.35) | SLC6A2SLC6A4SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230081390-A1 | INHIBITORS OF RAF KINASES | Pierre Fabre Médicament (FR) | 2023-03-16 | — | — | US | disclosed |
| EP-3941922-A1 | INHIBITORS OF RAF KINASES | Kinnate Biopharma Inc. (US) | 2022-01-26 | — | — | EP | disclosed |
| CN-113874381-A | Inhibitors of RAF kinase | 金耐特生物制药公司 | 2021-12-31 | — | — | CN | disclosed |
| WO-2020198058-A1 | INHIBITORS OF RAF KINASES | KINNATE BIOPHARMA INC. (US) | 2020-10-01 | — | — | WO | disclosed |
| WO-2020198058-A1 | INHIBITORS OF RAF KINASES | KINNATE BIOPHARMA INC. (US) | 2020-10-01 | — | — | WO | disclosed |
| US-20150025057-A1 | Triazine-oxadiazoles | NOVARTIS AG (CH) | 2015-01-22 | — | — | US | disclosed |
| US-8895733-B2 | Triazine-oxadiazoles | NOVARTIS AG (CH) | 2014-11-25 | — | — | US | disclosed |
| US-20140051676-A1 | Triazine-oxadiazoles | NOVARTIS AG (CH) | 2014-02-20 | — | — | US | disclosed |
| EP-2616465-A1 | TRIAZINE-OXADIAZOLES | Novartis AG (CH) | 2013-07-24 | — | — | EP | disclosed |
| WO-2012035023-A1 | TRIAZINE-OXADIAZOLES | NOVARTIS AG (CH) | 2012-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150025057-A1 | Triazine-oxadiazoles | OPRK1, OPRD1, OPRL1 | SLC6A2 2271/4885SLC6A4 1854/4885SLC6A3 2729/4885 |
| US-20230081390-A1 | INHIBITORS OF RAF KINASES | BRAF, RAF1, ARAF | SLC6A2 4848/4885SLC6A4 4865/4885SLC6A3 4772/4885 |
| US-20140051676-A1 | Triazine-oxadiazoles | OPRK1, OPRD1, OPRL1 | SLC6A2 2271/4885SLC6A4 1854/4885SLC6A3 2729/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.